Expression of c‐myc in non‐malignant and pre‐malignant gastrointestinal disorders

A monoclonal antibody 1‐6E10 against the protein product p62c‐myc of the c‐myc oncogene was used to assess, by immunohistology, a variety of non‐neoplastic and preneoplastic disorders of gastric and colonic mucosa. There were low levels of expression of the c‐myc oncogenic product in normal gastric and colonic tissue. In gastric mucosa, increased expression was observed with inflammatory, metaplastic and dysplastic histological appearances. In the normal colon low levels of expression were observed, but there was increased expression in inflammatory disorders including Crohn's disease and ulcerative colitis. There was also increased expression in colonic dysplasia associated with ulcerative colitis. The oncogene product was localized in the cytoplasm, nuclei and Golgi apparatus. C‐myc 1‐6E10 may therefore be used as a marker to identify the cellular proliferative response in gastric and colonic mucosa that is associated with inflammation as well as potentially neoplastic hyperproliferative states.

[1]  R. Camplejohn,et al.  DNA flow cytometry of histological material from dysplastic lesions of human gastric mucosa , 1986, The Journal of pathology.

[2]  J. Macartney,et al.  An immunohistochemical study of a colonic mucus antigen in normal and neoplastic gastrointestinal tissues , 1986, The Journal of pathology.

[3]  Eisenman Rn,et al.  Oncogenes with potential nuclear function: myc, myb and fos. , 1986 .

[4]  G. Evan,et al.  Characterisation of human myc proteins. , 1986, Current topics in microbiology and immunology.

[5]  J. Stewart,et al.  The tumour promoter 12-O-tetradecanoylphorbol-13-acetate increases the activities of some peroxisome-associated enzymes in in vitro cell culture. , 1986, British Journal of Cancer.

[6]  G K Lewis,et al.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product , 1985, Molecular and cellular biology.

[7]  A. Balmain,et al.  Immunocytochemical demonstration of p21 ras family oncogene product in normal mucosa and in premalignant and malignant tumours of the colorectum. , 1985, British journal of cancer.

[8]  D. Jewell,et al.  Immunohistologic demonstration of abnormal colonic crypt cell kinetics in ulcerative colitis. , 1985, Human pathology.

[9]  D. Spandidos,et al.  Immunohistochemical detection of the ras oncogene p21 product in an experimental tumour and in human colorectal neoplasms. , 1985, British Journal of Cancer.

[10]  E. Fontham,et al.  Proliferative and antigenic modifications in human epithelial cells in chronic atrophic gastritis. , 1985, Journal of the National Cancer Institute.

[11]  J. Stewart,et al.  Detection of the c-myc oncogene product in testicular cancer. , 1985, British Journal of Cancer.

[12]  H. Lachman,et al.  Expression of c-myc changes during differentiation of mouse erythroleukaemia cells , 1984, Nature.

[13]  Sunter Jp.  Cell proliferation in gastrointestinal carcinogenesis. , 1984 .

[14]  J. Bishop.  Cellular oncogenes and retroviruses. , 1983, Annual review of biochemistry.

[15]  A. Kirk,et al.  Rate and pattern of epithelial cell proliferation in ulcerative colitis. , 1981, Gut.

[16]  R. Lerner,et al.  Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Deschner,et al.  Tritiated thymidine incorporation into epithelial cells of normal-appearing colorectal mucosa of cancer patients. , 1977, Journal of the National Cancer Institute.